Simulations Plus, Inc. Aktie News

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today responded to the U.S. Food and Drug Administration's draft guidance on streamlined nonclinical safety studies for monospecific monoclonal antibodies. The guidance...

Shares of Simulations Plus had gained more than 20% as of midday Thursday. The company reported mixed results, but its guidance calls for revenue and earnings growth in fiscal 2026 despite a difficult environment.

Simulations Plus is a specialized in silico software-and-services platform. They help with model-informed, non-animal drug development. SLP's services help across discovery, development, and clinical operations. Software remains their main economic driver with higher margins. Services are growing faster and gradually increasing their share of total revenues but have lower margins.

Its full-year fiscal 2025 featured a double-digit revenue increase. As for the fourth quarter, its performance was mixed.

Simulations Plus, Inc. (SLP) Q4 2025 Earnings Call Transcript

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in cheminformatics, biosimulation, clinical operations solutions and medical communications that accelerate biopharma innovation, today reported financial results for its fourth quarter and fiscal 2025, ended August 31, 2025. Fourth Quarter 2025 Financial Hi...

NEWTOWN, Pa. , Nov. 28, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Simulations Plus, Inc. (NASDAQ: SLP), resulting from allegations of providing potentially misleading business information to the investing public.

NEWTOWN, Pa. , Nov. 10, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Simulations Plus, Inc. ("Simulations Plus") (NASDAQ: SLP), resulting from allegations of providing potentially misleading business information to the investing public.